CYXONE AB SK-75
Cyxone AB (publ), a clinical stage biotech company, develops disease modifying therapies for autoimmune and autoinflammatory diseases. Its product pipeline comprises Rabeximod, which is in phase II clinical development for the treatment of rheumatoid arthritis; and T20K for the treatment of multiple sclerosis and is in phase I trial. The company was founded in 2015 and is headquartered in Malmö, … Read more
Market Cap & Net Worth: CYXONE AB SK-75 (4CX)
CYXONE AB SK-75 (F:4CX) has a market capitalization of $77.00K (€75.01K) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #42680 globally and #6715 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CYXONE AB SK-75's stock price €0.00 by its total outstanding shares 375057984 (375.06 Million).
CYXONE AB SK-75 Market Cap History: 2018 to 2024
CYXONE AB SK-75's market capitalization history from 2018 to 2024. Data shows change from $88.85 Million to $77.00K (-70.27% CAGR).
CYXONE AB SK-75 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CYXONE AB SK-75's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 4CX by Market Capitalization
Companies near CYXONE AB SK-75 in the global market cap rankings as of March 18, 2026.
Key companies related to CYXONE AB SK-75 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
CYXONE AB SK-75 Historical Marketcap From 2018 to 2024
Between 2018 and today, CYXONE AB SK-75's market cap moved from $88.85 Million to $ 77.00K, with a yearly change of -70.27%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2024 | €77.00K | -98.96% |
| 2023 | €7.43 Million | -40.25% |
| 2022 | €12.44 Million | -78.58% |
| 2021 | €58.06 Million | -62.21% |
| 2020 | €153.61 Million | -1.24% |
| 2019 | €155.53 Million | +75.04% |
| 2018 | €88.85 Million | -- |
End of Day Market Cap According to Different Sources
On Dec 5th, 2025 the market cap of CYXONE AB SK-75 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $77.00K USD |
| MoneyControl | $77.00K USD |
| MarketWatch | $77.00K USD |
| marketcap.company | $77.00K USD |
| Reuters | $77.00K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.